Century Therapeutics (IPSC) Competitors

Century Therapeutics (NASDAQ:IPSC) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings.

Does the MarketBeat Community prefer IPSC or MNPR?

Monopar Therapeutics received 7 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 73.33% of users gave Monopar Therapeutics an outperform vote while only 67.27% of users gave Century Therapeutics an outperform vote.

Company	Underperform	Outperform
Century Therapeutics	Outperform Votes 37 67.27%	Underperform Votes 18 32.73%
Monopar Therapeutics	Outperform Votes 44 73.33%	Underperform Votes 16 26.67%

Which has more volatility and risk, IPSC or MNPR?

Century Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Do analysts rate IPSC or MNPR?

Century Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 1,269.86%. Monopar Therapeutics has a consensus target price of $43.00, indicating a potential upside of 6.83%. Given Century Therapeutics' higher probable upside, equities analysts clearly believe Century Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Monopar Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders hold more shares of IPSC or MNPR?

50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 6.8% of Century Therapeutics shares are held by company insiders. Comparatively, 34.9% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media favor IPSC or MNPR?

In the previous week, Century Therapeutics had 10 more articles in the media than Monopar Therapeutics. MarketBeat recorded 10 mentions for Century Therapeutics and 0 mentions for Monopar Therapeutics. Century Therapeutics' average media sentiment score of 0.90 beat Monopar Therapeutics' score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Century Therapeutics	Positive
Monopar Therapeutics	Neutral

Which has stronger earnings and valuation, IPSC or MNPR?

Monopar Therapeutics has lower revenue, but higher earnings than Century Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	$2.23M	27.83	-$136.67M	-$1.85	-0.39
Monopar Therapeutics	N/A	N/A	-$8.40M	-$1.97	-20.43

Is IPSC or MNPR more profitable?

Monopar Therapeutics has a net margin of 0.00% compared to Century Therapeutics' net margin of -4,837.73%. Century Therapeutics' return on equity of -61.66% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	-4,837.73%	-61.66%	-31.78%
Monopar Therapeutics	N/A	-107.21%	-87.57%

Summary

Century Therapeutics beats Monopar Therapeutics on 10 of the 15 factors compared between the two stocks.